Xiao-Ming Gao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Xiao-Ming Gao has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
Yan Zhang
Department of Immunology, Peking University Health Science Center, Peking University, Beijing, China
6 shared publicationsPing Lv
Department of Immunology, Peking University Health Science Center, Peking University, Beijing, China
5 shared publicationsWei Wang
Department of Immunology, Peking University Health Science Center, Beijing, China,1 Beijing Red Cross Blood Center, Beijing, China2
5 shared publicationsJincun Zhao
Department of Immunology, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100083, China
3 shared publications- Zhen-Dong Zhao
Department of Immunology, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100083, PR China
3 shared publications Furong Ren
Department of Immunology, Peking University Health Science Center, Beijing, China,1 Beijing Red Cross Blood Center, Beijing, China2
2 shared publications
Latest Publications
- 1 December 2009
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 6 (6) , 453-459
A Study on the Glycan Specificity of Natural Antibody Repertoires in Rodents
Inbred strains of mice and rats are widely used in preclinical investigations evaluating the effectiveness of glycan-based biomecines, however, the glycan specificity repertoires of serum Abs in rodents have not been fully characterized. In the present study, serum antibodies in naïve mice and rats of different inbred strains were analyzed for specificity against 4 representative carbohydrate structures including PGA (1,4-linked α-D-galactopyranosyluronic acids), β-glucan, mannan and α-glucan (dextran). Mannan was not recognized by serum Abs from any of the mouse and rat strains. Serum IgM in naïve F344, BN and Lewis rats recognized PGA and β-glucan and, less strongly, dextran. High titer circulating IgM against PGA were found in mice of BALB/c, C57BL/6, C3H/NeH and BXSB strains. C3H/NeH was the only strain which also produced low titer IgM against β-glucan and dextran. Age-related production of high titer IgM, IgA and IgG Abs against β-glucan was observed in BXSB mice. Intraperitoneal immunization of BALB/c and C57BL/6 mice with β-glucan elicited strong IgM responses, while immunization with PGA also led to an increase of anti-PGA IgM Ab titers. These results provide useful information on the characteristics of glycan-specific natural antibody repertoires in rodents.
- 1 December 2009
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 6 (6) , 453-459
A Study on the Glycan Specificity of Natural Antibody Repertoires in Rodents
Inbred strains of mice and rats are widely used in preclinical investigations evaluating the effectiveness of glycan-based biomecines, however, the glycan specificity repertoires of serum Abs in rodents have not been fully characterized. In the present study, serum antibodies in naïve mice and rats of different inbred strains were analyzed for specificity against 4 representative carbohydrate structures including PGA (1,4-linked α-D-galactopyranosyluronic acids), β-glucan, mannan and α-glucan (dextran). Mannan was not recognized by serum Abs from any of the mouse and rat strains. Serum IgM in naïve F344, BN and Lewis rats recognized PGA and β-glucan and, less strongly, dextran. High titer circulating IgM against PGA were found in mice of BALB/c, C57BL/6, C3H/NeH and BXSB strains. C3H/NeH was the only strain which also produced low titer IgM against β-glucan and dextran. Age-related production of high titer IgM, IgA and IgG Abs against β-glucan was observed in BXSB mice. Intraperitoneal immunization of BALB/c and C57BL/6 mice with β-glucan elicited strong IgM responses, while immunization with PGA also led to an increase of anti-PGA IgM Ab titers. These results provide useful information on the characteristics of glycan-specific natural antibody repertoires in rodents.
- 1 October 2009
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 6 (5) , 361-366
Elevated Levels of Serum IgA Against Saccharomyces Cerevisiae Mannan in Patients with Rheumatoid Arthritis
This study was undertaken to investigate whether levels of anti-Saccharomyces cerevisiae mannan antibodies (ASCMA) in human sera, a marker for several autoimmune diseases, correlate with rheumatoid arthritis (RA). ASCMA-IgA, -IgG and -IgM levels were measured with enzyme linked immunosorbent assays (ELISA) in patients with RA (n = 30) and 152 healthy adult controls. ASCMA-IgA prevalence was significantly higher in RA patients (40%) than in healthy subjects (5.3%). A strong correlation between levels of ASCMA-IgA and CRP (r = 0.695; p < 0.01) and ESR (r = 0.708; p < 0.01) in RA patients was observed. No significant differences in ASCMA-IgG or IgM levels were noted between RA patients and healthy control subjects in the present study. This result differs from previous reports. It remains to be evaluated whether elevated ASCMA-levels are common to all rheumatic disorders.
- 1 October 2009
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 6 (5) , 361-366
Elevated Levels of Serum IgA Against Saccharomyces Cerevisiae Mannan in Patients with Rheumatoid Arthritis
This study was undertaken to investigate whether levels of anti-Saccharomyces cerevisiae mannan antibodies (ASCMA) in human sera, a marker for several autoimmune diseases, correlate with rheumatoid arthritis (RA). ASCMA-IgA, -IgG and -IgM levels were measured with enzyme linked immunosorbent assays (ELISA) in patients with RA (n = 30) and 152 healthy adult controls. ASCMA-IgA prevalence was significantly higher in RA patients (40%) than in healthy subjects (5.3%). A strong correlation between levels of ASCMA-IgA and CRP (r = 0.695; p < 0.01) and ESR (r = 0.708; p < 0.01) in RA patients was observed. No significant differences in ASCMA-IgG or IgM levels were noted between RA patients and healthy control subjects in the present study. This result differs from previous reports. It remains to be evaluated whether elevated ASCMA-levels are common to all rheumatic disorders.
- Open Access
- 22 January 2009
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 69 (2) , 119-129
Elevated Expression of Transmembrane IL‐15 in Immune Cells Correlates with the Development of Murine Lupus: a Potential Target for Immunotherapy Against SLE
Presentation in trans by the Interleukin‐15 receptor α chain (IL‐15Rα) has been suggested as the main mechanism for IL‐15 anchoring to the cell surface, but it is also evident that IL‐15 can exist as a transmembrane protein. We herein demonstrate that replacement of the first 41 residues of human IL‐15 (hIL‐15) with Igκ chain leader sequence resulted in secretion of most of the recombinant hIL‐15 expressed in transfectant cells, thus identifying the transmembrane region of IL‐15. A fusion protein (hIL‐15Rα‐Fc) between the extracellular domain of hIL‐15Rα and the Fc fragment of IgG1 was prepared and shown to be able to bind with transmembrane IL‐15 (tmIL‐15). The level of tmIL‐15 expression in macrophages, activated T cells and B cells from 6‐month‐old BXSB male mice, an animal model for systemic lupus erythematosus (SLE), was significantly increased compared with that from BXSB females or young males. In addition, hIL‐15Rα‐Fc was able to block the T cell stimulating and anti‐apoptotic effect of the tmIL‐15‐positive BXSB macrophages in vitro. Intravenous administration of hIL‐15Rα‐Fc reduced the titre of autoantibodies against dsDNA and also proteinuria in aged BXSB males, implying that neutralization of IL‐15 activity in vivo may be an effective way of treating SLE.
- 22 January 2009
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 69 (2) , 119-129
Open AccessElevated Expression of Transmembrane IL‐15 in Immune Cells Correlates with the Development of Murine Lupus: a Potential Target for Immunotherapy Against SLE
Presentation in trans by the Interleukin‐15 receptor α chain (IL‐15Rα) has been suggested as the main mechanism for IL‐15 anchoring to the cell surface, but it is also evident that IL‐15 can exist as a transmembrane protein. We herein demonstrate that replacement of the first 41 residues of human IL‐15 (hIL‐15) with Igκ chain leader sequence resulted in secretion of most of the recombinant hIL‐15 expressed in transfectant cells, thus identifying the transmembrane region of IL‐15. A fusion protein (hIL‐15Rα‐Fc) between the extracellular domain of hIL‐15Rα and the Fc fragment of IgG1 was prepared and shown to be able to bind with transmembrane IL‐15 (tmIL‐15). The level of tmIL‐15 expression in macrophages, activated T cells and B cells from 6‐month‐old BXSB male mice, an animal model for systemic lupus erythematosus (SLE), was significantly increased compared with that from BXSB females or young males. In addition, hIL‐15Rα‐Fc was able to block the T cell stimulating and anti‐apoptotic effect of the tmIL‐15‐positive BXSB macrophages in vitro. Intravenous administration of hIL‐15Rα‐Fc reduced the titre of autoantibodies against dsDNA and also proteinuria in aged BXSB males, implying that neutralization of IL‐15 activity in vivo may be an effective way of treating SLE.
- 24 July 2007
- Published by Elsevier in International Immunopharmacology
- Vol. 7 (11) , 1414-1421
Apoptosis of murine lupus T cells induced by the selective cyclooxygenase-2 inhibitor celecoxib: Molecular mechanisms and therapeutic potential
- 24 July 2007
- Published by Elsevier in International Immunopharmacology
- Vol. 7 (11) , 1414-1421
Apoptosis of murine lupus T cells induced by the selective cyclooxygenase-2 inhibitor celecoxib: Molecular mechanisms and therapeutic potential
- Open Access
- 1 July 2007
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 14 (7) , 839-846
Comparison of Immunoglobulin G Responses to the Spike and Nucleocapsid Proteins of Severe Acute Respiratory Syndrome (SARS) Coronavirus in Patients with SARS
Both the nucleocapsid (N) and the spike (S) proteins of severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) are able to induce strong humoral responses in humans following an infection. To compare the immunoglobulin G (IgG) responses to the S and N proteins of SARS-CoV in SARS patients during the manifestation/convalescent period with those during the postinfection period, serum samples were collected from hospitalized SARS patients within 6 weeks after the onset of illness (set 1; 57 sequential samples from 19 patients) or 2 to 3 months after their recovery (set 2; 33 postinfection samples from 33 subjects). Serum samples from 100 healthy blood donors (set 3), collected in 2002, were also included. The specific IgG response to whole virus, the fragment from positions 450 to 650 of the S protein (S450-650), and the full-length N protein of SARS-CoV were measured by enzyme-linked immunosorbent assays (ELISAs). Western blot assays were carried out to confirm the ELISA results. Fifty-one of the serum samples in set 1 (89%) bound to the N protein, a proportion similar to that which recognized whole virus (79%) and the S-protein fragment (77%). All 33 serum samples from set 2 were strongly positive for N-protein-specific IgG, while 27 (82%) were positive for anti-S450-650 IgG. Two of the serum samples from set 3 were strongly positive for anti-N-protein IgG but not anti-S450-650 IgG. Similar levels of IgG responses to the S and N proteins were observed in SARS patients during the manifestation and convalescent stages. In the postinfection period, however, a number of patients had much lower serum IgG levels against S450-650 than against the N protein.
- 1 July 2007
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 14 (7) , 839-846
Open AccessComparison of Immunoglobulin G Responses to the Spike and Nucleocapsid Proteins of Severe Acute Respiratory Syndrome (SARS) Coronavirus in Patients with SARS
Both the nucleocapsid (N) and the spike (S) proteins of severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) are able to induce strong humoral responses in humans following an infection. To compare the immunoglobulin G (IgG) responses to the S and N proteins of SARS-CoV in SARS patients during the manifestation/convalescent period with those during the postinfection period, serum samples were collected from hospitalized SARS patients within 6 weeks after the onset of illness (set 1; 57 sequential samples from 19 patients) or 2 to 3 months after their recovery (set 2; 33 postinfection samples from 33 subjects). Serum samples from 100 healthy blood donors (set 3), collected in 2002, were also included. The specific IgG response to whole virus, the fragment from positions 450 to 650 of the S protein (S450-650), and the full-length N protein of SARS-CoV were measured by enzyme-linked immunosorbent assays (ELISAs). Western blot assays were carried out to confirm the ELISA results. Fifty-one of the serum samples in set 1 (89%) bound to the N protein, a proportion similar to that which recognized whole virus (79%) and the S-protein fragment (77%). All 33 serum samples from set 2 were strongly positive for N-protein-specific IgG, while 27 (82%) were positive for anti-S450-650 IgG. Two of the serum samples from set 3 were strongly positive for anti-N-protein IgG but not anti-S450-650 IgG. Similar levels of IgG responses to the S and N proteins were observed in SARS patients during the manifestation and convalescent stages. In the postinfection period, however, a number of patients had much lower serum IgG levels against S450-650 than against the N protein.
- 1 June 2007
- Published by American Society for Microbiology in Journal of Virology
- Vol. 81 (11) , 6079-6088
Identification and Characterization of Dominant Helper T-Cell Epitopes in the Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus
By using a series of overlapping synthetic peptides covering 98% of the amino acid sequence of the nucleocapsid protein (NP) of severe acute respiratory syndrome coronavirus (SARS-CoV), four helper T-cell (Th) epitopes (NP11, residues 11 to 25; NP51, residues 51 to 65; NP61, residues 61 to 75; and NP111, residues 111 to 125) in C57BL mice (H-2b), four (NP21, residues 21 to 35; NP91, residues 91 to 105; NP331, residues 331 to 345; and NP351, residues 351 to 365) in C3H mice (H-2k), and two (NP81, residues 81 to 95; and NP351, residues 351 to 365) in BALB/c mice (H-2d) have been identified. All of these peptides were able to stimulate the proliferation of NP-specific T-cell lines or freshly isolated lymph node cells from mice immunized with recombinant NP. Immunization of mice with synthetic peptides containing appropriate Th epitopes elicited strong cellular immunity in vivo, as evidenced by delayed-type hypersensitivity. Priming with the helper peptides (e.g., NP111 and NP351) significantly accelerated the immune response induced by recombinant NP, as determined by the production of NP-specific antibodies. When fused with a conserved neutralizing epitope (SP1143-1157) from the spike protein of SARS-CoV, NP111 and NP351 assisted in the production of high-titer neutralizing antibodies in vivo. These data provide useful insights regarding immunity against SARS-CoV and have the potential to help guide the design of peptide-based vaccines.
- 1 June 2007
- Published by American Society for Microbiology in Journal of Virology
- Vol. 81 (11) , 6079-6088
Identification and Characterization of Dominant Helper T-Cell Epitopes in the Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus
By using a series of overlapping synthetic peptides covering 98% of the amino acid sequence of the nucleocapsid protein (NP) of severe acute respiratory syndrome coronavirus (SARS-CoV), four helper T-cell (Th) epitopes (NP11, residues 11 to 25; NP51, residues 51 to 65; NP61, residues 61 to 75; and NP111, residues 111 to 125) in C57BL mice (H-2b), four (NP21, residues 21 to 35; NP91, residues 91 to 105; NP331, residues 331 to 345; and NP351, residues 351 to 365) in C3H mice (H-2k), and two (NP81, residues 81 to 95; and NP351, residues 351 to 365) in BALB/c mice (H-2d) have been identified. All of these peptides were able to stimulate the proliferation of NP-specific T-cell lines or freshly isolated lymph node cells from mice immunized with recombinant NP. Immunization of mice with synthetic peptides containing appropriate Th epitopes elicited strong cellular immunity in vivo, as evidenced by delayed-type hypersensitivity. Priming with the helper peptides (e.g., NP111 and NP351) significantly accelerated the immune response induced by recombinant NP, as determined by the production of NP-specific antibodies. When fused with a conserved neutralizing epitope (SP1143-1157) from the spike protein of SARS-CoV, NP111 and NP351 assisted in the production of high-titer neutralizing antibodies in vivo. These data provide useful insights regarding immunity against SARS-CoV and have the potential to help guide the design of peptide-based vaccines.
- 13 February 2007
- Published by Springer Nature in Cell Research
- Vol. 17 (6) , 556-564
Interaction between antigen presenting cells and autoreactive T cells derived from BXSB mice with murine lupus
Systemic lupus erythematosus (SLE) is a typical autoimmune disease involving multiple systems and organs. Ample evidence suggests that autoreactive T cells play a pivotal role in the development of this autoimmune disorder. This study was undertaken to investigate the mechanisms of interaction between antigen presenting cells (APCs) and an autoreactive T cell (ATL1) clone obtained from lupus-prone BXSB mice. ATL1 cells, either before or after γ-ray irradiation, were able to activate naive B cells, as determined by B cell proliferation assays. Macrophages from BXSB mice were able to stimulate the proliferation of resting ATL1 cells at a responder/stimulator (R/S) ratio of 1/2.5. Dendritic cells (DCs) were much more powerful stimulators for ATL1 cells on a per cell basis. The T cell stimulating ability of macrophages and B cells, but not DCs, was sensitive to γ-ray irradiation. Monoclonal antibodies against mouse MHC-II and CD4 were able to block DC-mediated stimulation of ATL1 proliferation, indicating cognate recognition between ATL1 and APCs. Our data suggest that positive feedback loops involving macrophages, B cells and autoreactive T cells may play a pivotal role in keeping the momentum of autoimmune responses leading to autoimmune diseases.
- 13 February 2007
- Published by Springer Nature in Cell Research
- Vol. 17 (6) , 556-564
Interaction between antigen presenting cells and autoreactive T cells derived from BXSB mice with murine lupus
Systemic lupus erythematosus (SLE) is a typical autoimmune disease involving multiple systems and organs. Ample evidence suggests that autoreactive T cells play a pivotal role in the development of this autoimmune disorder. This study was undertaken to investigate the mechanisms of interaction between antigen presenting cells (APCs) and an autoreactive T cell (ATL1) clone obtained from lupus-prone BXSB mice. ATL1 cells, either before or after γ-ray irradiation, were able to activate naive B cells, as determined by B cell proliferation assays. Macrophages from BXSB mice were able to stimulate the proliferation of resting ATL1 cells at a responder/stimulator (R/S) ratio of 1/2.5. Dendritic cells (DCs) were much more powerful stimulators for ATL1 cells on a per cell basis. The T cell stimulating ability of macrophages and B cells, but not DCs, was sensitive to γ-ray irradiation. Monoclonal antibodies against mouse MHC-II and CD4 were able to block DC-mediated stimulation of ATL1 proliferation, indicating cognate recognition between ATL1 and APCs. Our data suggest that positive feedback loops involving macrophages, B cells and autoreactive T cells may play a pivotal role in keeping the momentum of autoimmune responses leading to autoimmune diseases.
- 31 May 2005
- Published by Elsevier in Journal of Clinical Virology
- Vol. 33 (1) , 12-18
Development and evaluation of an enzyme-linked immunosorbent assay for detection of antibodies against the spike protein of SARS-coronavirus
- 31 May 2005
- Published by Elsevier in Journal of Clinical Virology
- Vol. 33 (1) , 12-18
Development and evaluation of an enzyme-linked immunosorbent assay for detection of antibodies against the spike protein of SARS-coronavirus
- 1 October 2004
- Published by Wiley in Phytotherapy Research
- Vol. 18 (10) , 857-861
Immunopotentiating effect of a ‘Yang’‐promoting formula of traditional Chinese medicine on aged female BALB/c mice
The ‘Yang’‐promoting traditional Chinese medicines (TCM) are used to boost vigor and enhance immunity in humans. In this study, the immunopotentiating effect of VI‐28, a ‘Yang’‐promoting TCM formula containing extracts of radix ginseng, cornu Cervi pantotrichum and radix Salvia miltiorrhizae, was investigated. Groups of 8‐month‐old female ex‐breeder BALB/c mice were fed on ordinary mouse food or food containing a low (0.5%) or high (2%) dose VI‐28 for up to 18 weeks. From week 6, mice on the TCM‐containing diet were much healthier, stronger and more alert than those on the normal mouse food. Furthermore, their thymuses were significantly bigger and heavier than those of the control mice. Histological examination revealed structural changes typical of thymic involution in mice of the control group, whilst the microstructure of thymuses from mice taking TCM‐containing food was comparable to that of mice of a much younger age, indicating a positive effect of VI‐28 on slowing down thymic involution. Functional analysis of splenocytes from mice of different groups suggested that oral administration of VI‐28 corrected the hyporesponsiveness of T lymphocytes in aged mice. These results have important implications for our understanding of the mechanisms of the immunoboosting effect of TCM. Copyright © 2004 John Wiley & Sons, Ltd.
- 1 October 2004
- Published by Wiley in Phytotherapy Research
- Vol. 18 (10) , 857-861
Immunopotentiating effect of a ‘Yang’‐promoting formula of traditional Chinese medicine on aged female BALB/c mice
The ‘Yang’‐promoting traditional Chinese medicines (TCM) are used to boost vigor and enhance immunity in humans. In this study, the immunopotentiating effect of VI‐28, a ‘Yang’‐promoting TCM formula containing extracts of radix ginseng, cornu Cervi pantotrichum and radix Salvia miltiorrhizae, was investigated. Groups of 8‐month‐old female ex‐breeder BALB/c mice were fed on ordinary mouse food or food containing a low (0.5%) or high (2%) dose VI‐28 for up to 18 weeks. From week 6, mice on the TCM‐containing diet were much healthier, stronger and more alert than those on the normal mouse food. Furthermore, their thymuses were significantly bigger and heavier than those of the control mice. Histological examination revealed structural changes typical of thymic involution in mice of the control group, whilst the microstructure of thymuses from mice taking TCM‐containing food was comparable to that of mice of a much younger age, indicating a positive effect of VI‐28 on slowing down thymic involution. Functional analysis of splenocytes from mice of different groups suggested that oral administration of VI‐28 corrected the hyporesponsiveness of T lymphocytes in aged mice. These results have important implications for our understanding of the mechanisms of the immunoboosting effect of TCM. Copyright © 2004 John Wiley & Sons, Ltd.